Phase 3 Alzheimer's Disease Trial, Recruiting NCT07062198 Sponsor: ScandiBio Therapeutics AB Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Recruiting

NCT07062198
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men and women aged 50 or older who are not able to have children
  • People who have been diagnosed with Alzheimer's disease and scored at or above certain thresholds on two standard memory and mood assessment tools at the screening visit (confirm with trial site)
  • People whose Alzheimer's disease treatments and overall condition have been stable for at least one month
  • Women who could still become pregnant may be eligible if they have had a tubal ligation or hysterectomy, or have gone through menopause (defined as no menstrual period for 12 months, with a blood test to confirm if there is any uncertainty)
  • People who are able to give written consent to take part, either personally or through a legal representative

Who may not be able to join:

  • People who have had a stroke at any point in the past
  • People who have had a brain injury within the last 14 days
  • People with depression that is not currently well controlled
  • People with type 1 or type 2 diabetes that is not well controlled (based on a specific blood sugar measurement)
  • People with severe difficulty swallowing
  • People who are fed through a stomach tube (PEG feeding)
  • People with ongoing, long-term diarrhoea
  • People with chronic kidney disease above a certain level of severity (confirm with trial site)
  • People with active asthma at the time of their screening visit
  • People with a history of a rare inherited condition called phenylketonuria
  • People with a known allergy to any substances used in the study
  • People with a known active cancer
  • People who have used dietary supplements such as vitamins, omega-3 products, or plant sterol/stanol products within one week before joining
  • People who have used antibiotics or other antimicrobial medicines within one week before joining
  • People with a history of drug or alcohol misuse
  • People whom the trial investigator considers unsuitable for any reason, such as concerns about their ability to follow the study requirements
  • People who have taken part in another clinical trial involving an unapproved drug within three months before this study begins

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sevki SAHIN, Prof. Dr., Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences Istanbul 34766, Turkiye

Phone: +90 216 606 33 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
ScandiBio Therapeutics AB
Registry
ClinicalTrials.gov
Start date
12 September 2025
Est. completion
1 September 2026

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score from baseline to end-of-treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov